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Pharmacogenetics of Modafinil after sleep loss:
Catechol-O-methyltransferase genotype modulates waking
functions but not recovery sleep
Abstract
Sleep loss impairs waking functions and is homeostatically compensated in recovery sleep. The
mechanisms underlying the consequences of prolonged wakefulness are unknown. The stimulant
modafinil may promote primarily dopaminergic neurotransmission. Catechol-O-methyltransferase
(COMT) catalyzes the breakdown of cerebral dopamine. A functional Val158Met polymorphism
reduces COMT activity, and Val/Val homozygous individuals presumably have lower dopaminergic
signaling in the prefrontal cortex than do Met/Met homozygotes. We quantified the contribution of this
polymorphism to the effects of sleep deprivation and modafinil on subjective state, cognitive
performance, and recovery sleep in healthy volunteers. Two-time 100 mg modafinil potently improved
vigor and well-being, and maintained baseline performance with respect to executive functioning and
vigilant attention throughout sleep deprivation in Val/Val genotype subjects but was hardly effective in
subjects with the Met/Met genotype. Neither modafinil nor the Val158Met polymorphism affected
distinct markers of sleep homeostasis in recovery sleep. In conclusion, dopaminergic mechanisms
contribute to impaired waking functions after sleep loss.
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Abstract 
Sleep loss impairs waking functions and is homeostatically compensated in recovery sleep. 
The mechanisms underlying the consequences of prolonged wakefulness are unknown. The stimulant 
modafinil may promote primarily dopaminergic neurotransmission. Catechol-O-methyltransferase 
(COMT) catalyzes the breakdown of cerebral dopamine. A functional Val158Met polymorphism 
reduces COMT activity, and Val/Val homozygous individuals presumably have lower dopaminergic 
signaling in prefrontal cortex than Met/Met homozygotes. We quantified the contribution of this 
polymorphism to the effects of sleep deprivation and modafinil on subjective state, cognitive 
performance, and recovery sleep in healthy volunteers. Two-time 100 mg modafinil potently 
improved vigor and well-being, and maintained baseline performance throughout sleep deprivation on 
executive functioning and vigilant attention in Val/Val genotype, yet was hardly effective in Met/Met 
genotype. Neither modafinil or Val158Met polymorphism affected distinct markers of sleep 
homeostasis in recovery sleep. In conclusion, dopaminergic mechanisms contribute to impaired 
waking functions after sleep loss. 
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Introduction 
Sleep and wakefulness form a daily continuum, yet the genetic and neurochemical 
mechanisms underlying sleep-wake regulation are largely unknown. Clinically defined sleep disorders 
such as narcolepsy, obstructive sleep apnea and behaviorally induced insufficient sleep syndrome 
(BIISS, “sleep deprivation”), but also shift work, jet lag and voluntary sleep restriction are highly 
prevalent in the modern “24/7- society”. Non-restorative and insufficient sleep leads in many people 
to excessive daytime sleepiness, which is strongly associated with the risk of accidents and human 
errors (1). The impact of insufficient sleep on health and well-being has developed to a major public 
health concern (2). The availability of effective countermeasures to reduce sleepiness and behavioral 
and cognitive consequences following sleep loss is of clinical and public importance. This fact is 
highlighted by the ubiquitous use of pharmacological agents to promote wakefulness and maintain 
alertness after insufficient sleep. Whereas caffeine is considered the most often consumed substance 
in the world, the stimulant modafinil, because of its apparent positive safety profile, is becoming 
increasingly popular. 
Modafinil in daily doses of 100 to 400 mg is clinically used as first-line treatment of 
pathological sleepiness in patients with narcolepsy (3). Controlled studies also demonstrated its 
efficacy as an adjunct therapy of subjective sleepiness and fatigue in various diseases such as 
obstructive sleep apnea (4), shift-work sleep disorder (5), Parkinson’s disease (6), major depressive 
disorder (7), and multiple sclerosis (8). Although it is certain that the pharmacological profile of 
modafinil differs from amphetamine-like compounds, its mode of action is controversial. The 
available evidence ranging from genetically modified mice to in vitro electrophysiology suggests that 
the drug stimulates wakefulness primarily by modifying dopaminergic and (nor)adrenergic 
neurotransmission (9). 
Consistent with this notion, clinical observations in narcolepsy indicate that the response to 
modafinil is modulated by a functional genetic variation in the important breakdown enzyme of 
cortical catecholamines, catechol-O-methyltransferase (COMT) (10). The human COMT gene is 
located on chromosome 22q11.2, and contains a functional single nucleotide polymorphism (SNP) 
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that alters the amino acid sequence of the membrane-bound COMT protein at codon 158 from valine 
(Val) to methionine (Met; SNP-ID: rs4680) (11). No equivalent COMT polymorphism was found in 
any other species examined to date, including non-human primates (12). Europeans have nearly equal 
frequencies of Val (~ 48 %) and Met (~ 52 %) alleles, whereas the Val allele is much more common in 
populations from other parts of the world (12). Individuals homozygous for the Val allele show more 
COMT protein in post-mortem brain tissue than individuals with two Met alleles (13). Moreover, the 
Val/Val genotype shows 3- to 4-fold higher COMT activity and presumably lower dopaminergic 
signaling in prefrontal cortex than the Met/Met genotype (13, 14). Strong evidence suggests that the 
Val158Met polymorphism of COMT affects the prefrontal cortex and associated areas, and modulates 
executive functioning, working memory and measures of attention (15). 
The sleepiness in narcoleptic patients may be comparable to the sleepiness experienced by 
healthy subjects after two days without sleep (16). Sleep loss not only increases sleepiness, but also 
affects mood, impairs executive functions, working memory and sustained attention (17). Moreover, it 
is highly reliably compensated by enhanced non-rapid-eye-movement (nonREM) sleep intensity as 
measured by low-frequency (delta) EEG activity in recovery sleep (18). Decreased activation and 
function of the prefrontal cortex may be critical for the waking consequences of sleep loss (19) (for 
recent review, see (20)). While the effects of modafinil on quantitative sleep EEG measures in 
humans are not known, the drug improves impaired alertness and performance on cognitive tasks after 
36 to 85 hours of prolonged waking (9, 21). Nevertheless, the subjective and objective efficacy are 
variable and return to pre-sleep-deprivation performance is not usually noted (21, 22). 
We combined pharmacogenetic, pharmacokinetic, neuropsychologic and polysomnographic 
methods, to delineate a dopaminergic mechanism in human sleep-wake regulation,. Based on the 
evidence presented above, we hypothesized that sleep deprivation and modafinil affect the same 
neuronal processes, and that the efficacy of the stimulant to reverse sleep-loss-induced changes in 
subjective state, cognitive functions and sleep are modulated by the Val158Met polymorphism of 
COMT. Indeed, we found that modafinil potently improves vigor and subjective well-being, and 
maintains stable performance on tasks of executive functioning and vigilant attention throughout 
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40 hours prolonged waking in the Val/Val genotype, whereas it is virtually ineffective in the Met/Met 
genotype. By contrast, modafinil does not affect well-established, wakefulness-induced sleep and 
sleep EEG changes in recovery sleep in either genotype. These findings show that mechanisms 
involving prefrontal cortex dopamine contribute to distinct aspects of impaired subjective state and 
cognitive performance after sleep deprivation, but are not critical for the homeostatic regulation of 
low-frequency delta activity in the nonREM sleep EEG. 
 
Results 
Two groups of healthy men homozygous for the Val/Val (n = 10) and Met/Met (n = 12) 
genotypes of the functional Val158Met polymorphism of COMT were prospectively enrolled into this 
study (see supplementary information). The groups were carefully matched for age, body-mass-index, 
habitual alcohol and caffeine consumption, trait anxiety, subjective daytime sleepiness, as well as 
chronotype (Table 1; for nocturnal melatonin profile, see supplementary Fig. S1). A screening night 
in the sleep laboratory demonstrated that all participants were good sleepers with no sleep 
disturbances. 
 
Modafinil concentration in saliva 
All volunteers completed under constant supervision two 40-hour periods of prolonged 
wakefulness in the sleep laboratory (Fig. 1). After 11 and 23 hours waking they received 100 mg 
modafinil and placebo in randomized, double-blind, cross-over fashion. Prior to drug intake, 
modafinil was below the limit of detection in all subjects. Whereas the pharmacokinetics after the first 
capsule did not differ between the two genotypes, the maximum concentration after the second 
capsule occurred earlier and was higher in Val/Val than in Met/Met allele carriers (Fig. 2). Clearance 
from saliva following 4 hours after the second dose, and the mean concentration of modafinil one 
hour before initiation of recovery sleep (0.11 ± 0.01 vs. 0.12 ± 0.01 μg/ml) were similar in both 
groups. 
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Modafinil consistently improves subjective state after sleep deprivation in Val/Val genotype only 
Previous research indicated that low-dose modafinil is not consistently associated with 
subjectively perceived elation or stimulation after sleep deprivation (22). The subjective perception of 
the stimulant effects of modafinil was quantified 4 hours after intake of each capsule, at the time of 
the expected maximum of the drug in saliva (9). The “stimulant effects score” was invariably higher 
after active treatment than after placebo in subjects with the Val/Val genotype (first capsule: 11.3 ± 
2.2 vs. 5.7 ± 1.3, p < 0.004, paired t-test; second capsule: 15.2 ± 3.0 vs. 3.3 ± 1.2, p < 0.002). By 
contrast, the score was not different between verum and placebo in Met/Met allele carriers (first 
capsule: 9.1 ± 2.4 vs. 4.7 ± 1.6, p > 0.07; second capsule: 7.8 ± 1.7 vs. 3.8 ± 1.6, p > 0.2). After sleep 
deprivation, the subjective effects of modafinil differed significantly between the two genotypes (p < 
0.04, unpaired t-test). 
To examine whether the different subjective effects reflected the initially higher modafinil 
concentration in Val/Val allele carriers, the Spearman rank-correlation coefficient between the mean 
concentration at 30 and 60 minutes after drug intake and the stimulant effect score after the second 
capsule was computed. No significant relationship emerged (r = 0.1, p = 0.63, n = 22). However, 
subjects with the Val/Val genotype tended to correctly assign verum and placebo capsules more often 
than subjects with the Met/Met genotype (90 vs. 66 % correct, p = 0.09, Fisher’s exact test). 
Next we analyzed the effects of sleep deprivation and modafinil on subjective symptoms of 
fatigue, anger, vigor and depression, as quantified with a validated German translation of the profile 
of mood states (POMS) (23). These analyses revealed that sleep deprivation roughly doubled fatigue 
and slightly increased anger. Irrespective of genotype, modafinil was ineffective to mitigate these 
reductions in subjective state (data not shown). On the contrary, the drug attenuated the typical drop 
in vigor associated with prolonged wakefulness. This effect was restricted to the Val/Val genotype and 
completely lacking in the Met/Met genotype (Fig. 3A). Moreover, in both baseline and sleep deprived 
state, vigor was higher in Val/Val than Met/Met allele carriers. Neither sleep deprivation nor genotype 
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affected symptoms of depression as measured with the POMS. Nevertheless, depressive state after 
sleep deprivation was lower in the Val/Val genotype after modafinil than after placebo (Fig. 3B). The 
values did not differ in the Met/Met genotype. 
To further investigate whether modafinil differently affected subjective well-being after sleep 
deprivation, the objective “Befindlichkeits-Skala” (Bf-S scale) of van Zerssen was used (24). Sleep 
deprivation reduced well-being and modafinil improved it in both genotypes. Interestingly, the 
presence of two Val alleles of COMT enhanced the drug’s efficacy. Subjects with the Val/Val 
genotype scored similar as in baseline after drug intake following sleep deprivation, whereas 
modafinil produced significantly less improvement in subjects with the Met/Met genotype (Fig. 3C). 
 
Modafinil maintains cognitive performance during sleep deprivation in Val/Val genotype only 
Redundancy on a random number generation (RNG) task provides a sensitive index of 
subjects’ ability to update and monitor information (25). This aspect of executive functioning is 
particularly responsive to the detrimental effects of prolonged wakefulness (26). When compared to 
placebo, modafinil maintained low redundancy after sleep deprivation in both genotypes (Fig. 4, top 
panels). Nevertheless, the drug effect was more pronounced in the Val/Val genotype than in the 
Met/Met genotype. 
Measures of working memory are vulnerable to sleep loss (17). To investigate whether 
modafinil differently affected working memory after sleep deprivation in Val/Val and Met/Met allele 
carriers, subjects performed a visual 2-back task on day 1 and day 2 of prolonged wakefulness. 
Irrespective of genotype, sleep deprivation reduced response speed and roughly doubled the 
percentage of incorrect responses (Table 2). Modafinil attenuated these impairments. After drug 
intake, speed and accuracy after sleep deprivation did no longer differ from baseline in either 
genotype. 
Performance on the psychomotor vigilance task (PVT) is a sensitive measure of sustained 
vigilant attention, which is normally impaired after prolonged wakefulness (17). Across the first 16-20 
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hours of wakefulness, Val/Val and Met/Met allele carriers maintained almost lapse-free, fast and stable 
PVT performance in placebo and modafinil conditions (Fig. 4, lower panels). Afterwards, in the 
placebo condition, the number of response lapses increased and reaction times became longer and 
more variable. Performance was worst when testing occurred in the morning of day 2 of prolonged 
wakefulness. Most intriguingly, low-dose modafinil fully eliminated the wakefulness-induced 
impairment of sustained vigilant attention in the Val/Val genotype (p > 0.2 for factor ‘session’ for all 
above PVT measures), whereas it was virtually ineffective in the Met/Met genotype  (p < 0.0001). By 
contrast, the number of false responses in the absence of stimuli (sometimes referred to as “errors of 
commission”) did not differ between treatments and genotypes (data not shown). This observation 
suggests that lack of motivation was not critical for the reduced efficacy of modafinil in the Met/Met 
genotype. 
 
Modafinil does not affect established markers of sleep homeostasis in recovery sleep 
The homeostatic facet of sleep regulation refers to the highly reliable finding in animals and 
humans that recovery sleep after prolonged waking occurs with reduced latency and is more intense 
than baseline sleep (18). In both genotypes and irrespective of treatment, the time for subjects to fall 
asleep was similarly reduced and the duration of deep slow wave sleep (nonREM sleep stages 3 & 4) 
was equally enhanced after sleep deprivation when compared to baseline (Figs. 5A & 5B). 
Slow, rhythmic oscillations in nonREM sleep are a well-established physiological marker of 
sleep need and sleep intensity. The prevalence and amplitude of EEG oscillations in the 0.75-2.0 Hz 
range (low-frequency delta activity) was quantified with all-night spectral analysis in baseline and 
recovery sleep. This frequency band most sensitively reflects the putative effects of genetic variation 
and caffeine on sleep homeostasis (27-29). Sleep deprivation similarly increased low-frequency delta 
activity by 47-50 % in both Val/Val and Met/Met allele carriers (Fig. 5C). Modafinil did not affect the 
magnitude of this increase in either genotype. These findings demonstrate that in contrast to 
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subjective state and distinct aspects of cognitive performance, modafinil and the Val158Met 
polymorphism of COMT have no significant effects on recovery sleep after sleep deprivation. 
 
Discussion 
Here we show that the functional Val158Met polymorphism of COMT strongly modulates the 
efficacy of low-dose modafinil on subjective state and cognitive performance after sleep deprivation. 
The study provides the first example of a pharmacological intervention, which sustains high and 
stable waking functions throughout two days and one night without sleep in a genetically distinct 
group of healthy individuals. Because the COMT Val158Met polymorphism and also modafinil 
change dopaminergic signaling in prefrontal cortex (13, 14, 30, 31), we conclude that altered 
dopaminergic neurotransmission contributes to impaired well-being and cognitive performance after 
sleep loss. By contrast, neither COMT genotype or modafinil affect well-established, sleep-
deprivation-induced changes in recovery sleep after sleep deprivation. These findings demonstrate 
that the effects of sleep loss on waking neurobehavioral functions and distinct characteristics of sleep 
physiology depend on different mechanisms in humans. 
To follow the pharmacokinetics of modafinil in Val/Val and Met/Met allele carriers, we 
developed a novel LC-MS/MS method to quantify modafinil levels in saliva (see supplementary 
information). Consistent with data from plasma, we found that the drug is readily absorbed in young 
men and the peak concentration is reached at 2-4 hours after oral administration (3, 9). Modafinil 
levels differed significantly between the genotypes one hour after the second capsule intake. It cannot 
be excluded that this pharmacokinetic difference contributed to some modafinil-induced differences in 
state and performance following sleep deprivation. Nevertheless, modafinil is not known as a 
substrate of COMT, and the time course of drug concentration in the β-phase (final 3 measurements) 
indicates that modafinil metabolism and elimination are independent of COMT genotype. To our 
knowledge, modafinil is no substrate of COMT. Esterase enzymes in the liver are primarily 
responsible for the hydrolytic deamination of the drug to modafinil acid, and cytochrome P450 (CYP) 
Bodenmann et al. 
 10
3A4 converts this inactive metabolite to modafinil sulfone (9). However, modafinil is a substrate of P-
glycoprotein, which is encoded by the multi-drug resistance gene MDR1, and inhibits and induces, 
respectively, the human CYP isoenzymes 2C19 and 3A4/5. The genes of these proteins are 
polymorphic and play important roles for inter-individual differences in absorption and metabolism of 
drugs. It can not be excluded that the distribution of alleles and genotypes in MDR1 and CYP 
isoenzymes differed between Val/Val and Met/Met allele carriers. The possibility that polymorphisms 
in these genes interact with the Val158Met polymorphism of COMT and modulate the 
pharmacodynamics and pharmacokinetics of modafinil is intriguing and warrants further 
investigation. 
Low-dose modafinil does not reliably enhance cognitive task performance in non-sleep-
deprived subjects (32, 33). Similarly, the drug’s efficacy to reduce subjective and objective measures 
of sleepiness after sleep deprivation differs widely among individuals (22). Our data provide the first 
demonstration that the Val158Met polymorphism of COMT contributes to these inter-individual 
differences in healthy adults. Two-time 100 mg modafinil, the lowest recommended dose in 
narcolepsy, consistently improved subjective state and maintained executive functioning and vigilant 
attention throughout 40 hours of prolonged wakefulness in the Val/Val genotype, but was virtually 
ineffective in the Met/Met genotype. Based on the notion that this genetic variation affects synaptic 
dopamine levels in the prefrontal cortex (13), our data suggest that prefrontal cortex dopamine is 
critically involved in subjective and objective impairments from sleep deprivation. Frontal brain 
structures and associated functions are especially vulnerable to the effects of sleep loss (20). Medial 
frontal and prefrontal structures together with anterior cingulate cortex and thalamus are important for 
emotional processing, executive functions and attentional control (34). Modafinil increases blood flow 
in these cerebral regions in highly functional (35), as well as in impaired cognitive state such as after 
sleep loss (36). The recruitment of cortical and subcortical activation by modafinil may primarily 
reflect dopaminergic effects (30, 31, 37), although other mechanisms are also involved (9). The 
COMT genotype was previously proposed to modulate the response of the prefrontal cortex to 
increased dopamine according to an inverted, U-shaped response curve (38). Our observations are 
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compatible with this hypothesis. They suggest that the drug efficiently mitigates impaired subjective 
state and cognitive performance after sleep loss in Val/Val genotype who exhibit relatively deficient 
dopamine signaling. By contrast, the drug is hardly effective in Met/Met genotype with relatively 
higher dopaminergic tone at synapses where COMT activity is critical. 
An important impact of the Val158Met of COMT polymorphism on daytime functioning was 
previously found in patients with narcolepsy. Specifically, a sexual dimorphism and a strong effect of 
genotype on disease severity were reported (39). Women narcoleptics with high COMT activity fall 
asleep twice as fast during the multiple sleep latency test (3 min) than those with low COMT activity 
(6 min). An opposite relationship, although less pronounced (5.6 vs. 4.1 min), is observed in men 
(39). Inspection of patient histories revealed that also the response to treatment with modafinil to 
control excessive daytime sleepiness differs between COMT genotypes. Patients (female and male) 
with the Val/Val genotype need a higher daily dose (329.2 mg) than patients with the Met/Met 
genotype (241.0 mg) (10). A comparison of these data with our findings is difficult, because different 
outcome variables and subject populations were studied. Nevertheless, COMT genotype may 
distinctly modulate the individual response to modafinil in narcolepsy patients undergoing long-term 
pharmacotherapy and in healthy men after acute drug administration. This notion is supported by 
functional brain imaging data showing that four-week modafinil intake decreases cerebral blood flow 
in fronto-temporal cortices in narcoleptic patients (40), whereas no such decrease is observed after 
single-dose administration in healthy volunteers (35). The reasons for this discrepancy are unknown. 
Previous reports postulate that the sleep rebound following modafinil-induced wakefulness is 
reduced or even absent when compared to sleep deprivation (41, 42). While this finding is 
controversial (43), it would suggest that modafinil could compensate for changes in the brain that are 
the physiological consequences of prolonged waking. These changes are reliably and predictably 
reflected in recovery sleep by shortened sleep latency, prolonged slow wave sleep and increased slow 
rhythmic oscillations in nonREM sleep EEG (18). They can normally be reversed only by sleep. 
Modafinil had no effect on recovery sleep, neither in the Val/Val genotype who maintained baseline 
levels of executive functioning and sustained attention throughout 40 hours without sleep, or in the 
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Met/Met genotype who showed wakefulness-induced impaired waking functions. These observations 
challenge the hypothesis that modafinil inhibits the homeostatically regulated increase in deep 
nonREM sleep duration and intensity following prolonged wakefulness. In addition, the data suggest 
that the effects of sleep loss on daytime functioning and the sleep EEG are separately regulated. 
 
Methods 
Genotyping and subject recruitment 
The study protocol and all experimental procedures were reviewed and approved by the local 
ethics committee for research on human subjects, and conducted in accordance with the principles of 
the Declaration of Helsinki. 
A blood sample for genotyping was obtained from a total of 88 respondents to public 
advertisements looking for participants in this study. Genomic DNA was extracted from 3 ml fresh 
blood and used for the allelic discrimination of the Val158Met SNP (NCBI SNP-ID: rs4680) of the 
COMT gene. Twenty-two young men (age range: 20-29 years) were selected based on their 
Val158Met genotype of COMT and paid for participation. Ten individuals were homozygous Val/Val 
allele carriers, and 12 individuals were homozygous Met/Met allele carriers. The two groups were 
carefully matched for age, body-mass-index, habitual alcohol and caffeine consumption, anxiety 
(Trait Anxiety Inventory (44)), subjective daytime sleepiness (Epworth Sleepiness Scale (45)), and 
chronotype (Horne-Östberg Morningness-Eveningness Questionnaire (46) and Munich ChronoType 
Questionnaire (47)). All screening and pre-experimental procedures, as well as the sleep and sleep 
deprivation protocol were the same as in or adapted from previous studies (see supplementary 
information and references (26, 48) for details). 
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Modafinil capsules and quantification of modafinil concentration in saliva 
Two doses of 100 mg modafinil in the form of capsules were administered to all subjects after 
11 and 23 hours of prolonged wakefulness according to a randomized, double-blind, placebo-
controlled, cross-over design. The capsules were produced by homogenizing commercial 
Modasomil 100® tablets (distribution: Globopharm AG, Küsnacht, Switzerland) with mannitol 
(manufacturer: Siegfried Ltd., Zofingen, Switzerland). Identical placebo capsules contained only 
mannitol. 
Saliva samples for modafinil quantification were collected in 15 ml centrifuge tubes (Techno 
Plastic Products AG, Switzerland) immediately before the first capsule administration and at defined 
time points during prolonged wakefulness. The samples were stored at -80 °C for later analyses with a 
novel LC-MS/MS method developed in our Institute (see supplementary information and Table S1). 
 
Subjective state and cognitive performance 
On day 1 and day 2 of prolonged wakefulness, subjects completed at 16:45 h a validated 
German translation of the profile of mood state (POMS) (23), and at 10:45 h van Zerssen’s 
“Befindlichkeits-Skala” (Bf-S scale) for objective evaluation of subjective well-being (24). Four 
hours after capsule intake, the participants filled in a 20-item questionnaire about the subjective 
stimulant effects of the drug. This scale was developed by our group in the realm of previous 
investigations on the effects of caffeine during sleep deprivation (48). The possible answers to the 
questions whether common effects of stimulants were present or not were: not at all (scored as 0), a 
little (1), quite a bit (2), and very much (3) (total score: 0-60). 
In each study block, the participants completed 14 sessions of cognitive testing at 3-h 
intervals during a 40-hour prolonged waking period. Each session consisted of a random number 
generation (RNG) task (26, 49), preceded by a psychomotor vigilance task (PVT) (17) (for detailed 
information, see supplementary information). On the evening of the adaptation night in each block, 
the subjects completed the tasks once to familiarize themselves with them. 
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A verbal 2-back task to quantify working memory function was administered at 14:45 h on 
day 1 and day 2 of prolonged wakefulness. Performance on an intermediate level of task difficulty 
(2-back) was recently shown to be enhanced by 200 mg modafinil after over-night sleep deprivation 
(36). 
 
All-night polysomnography 
Continuous all-night polysomnographic recordings were performed during all nights. The 
EEG (data of derivation C3A2 are reported here), electrooculogram (EOG), mental electromyogram 
(EMG), and electrocardiogram (ECG) were recorded using Rembrandt Datalab® (Version 8; Embla 
Systems, Broomfield, CO, USA) and the polygraphic amplifier Artisan®. Analog signals were 
conditioned by a high-pass filter (EEG: -3 dB at 0.15 Hz; EMG: 10 Hz; ECG: 1 Hz) and an anti-
aliasing low-pass filter (-3 dB at 67.2 Hz), digitized and transmitted via fiber-optic cables to a 
personal computer. Data were sampled with a frequency of 256 Hz. The sleep stages were visually 
scored for 20-s epochs according to standard criteria (50) using Rembrandt Analysis Manager® 
(Version 8; Embla Systems, Broomfield, CO, USA). The EEG power spectra of consecutive 20-s 
epochs (average of 5 4-s epochs, FFT routine, Hanning window, frequency resolution 0.25 Hz) were 
calculated with MATLAB® (The MathWorks Inc, Natick, MA, USA), and matched with the sleep 
scores. Twenty-second epochs with movement- and arousal-related artifacts were visually identified 
and excluded. 
 
Data analyses and statistics 
All statistical analyses were performed with SAS® 8.02 software (SAS Institute, Cary, NC, 
USA). The time courses of modafinil in saliva, subjective state, redundancy on RNG, working 
memory, performance on PVT, sleep latency, slow wave sleep, as well as changes in EEG low-
frequency delta activity in nonREM sleep as a function of sleep deprivation and modafinil treatment 
in COMT Val/Val and Met/Met allele carriers were analyzed. Variables that were not normally 
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distributed (absolute EEG power values, reaction times and response lapses) were transformed to 
approximate a normal distribution. Two- and 3-way, mixed-model analyses of variance (ANOVA) 
with the between-subject factor ‘genotype’ (Val/Val, Met/Met) and the within-subject factors 
‘condition’ (mean baseline, SD-placebo, SD-modafinil), ‘treatment’ (modafinil, placebo), ‘session’ 
(14 assessments during prolonged waking), or ‘time’ of saliva collection for modafinil determination 
(10 time points), as well as their interactions were performed. Analyses involving the between-subject 
factor “order” (placebo-modafinil, modafinil-placebo) revealed no significant main effect or 
interactions. The significance level was set at α < 0.05. If not stated otherwise, only significant effects 
of factors and interactions are mentioned. Two-tailed, paired and unpaired t-tests to localize 
differences within and between groups were only performed if respective main effects or interactions 
of the ANOVA were significant. 
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Figure legends 
Figure 1. Schematic illustration of experimental protocol. Twenty-two healthy young men completed 
two experimental blocks separated by 1 week consisting of adaptation and baseline nights, 40-hours 
of prolonged wakefulness, and recovery night. The sleep deprivation period is highlighted here. Time 
awake and clock time are rounded up to the nearest hour. After 11 and 23 hours of wakefulness 
(vertical dashed lines) subjects received 100 mg modafinil or placebo according to a randomized, 
double-blind, cross-over design. In the same block subjects received either two capsules of modafinil 
or placebo, respectively. 
1. Subjective stimulant effects scale - 22:45/10:45 h. 
2. Profile of mood states (POMS) - 16:45 h. 
3. Objective evaluation of subjective well-being (van Zerssen’s Bf-S scale) - 10:45 h. 
4. Two-back task - 14:45 h. 
Arrows indicate test sessions comprising a psychomotor vigilance task (PVT) followed by a random 
number generation task (RNG) conducted at 3-hour intervals beginning 30 minutes after awakening. 
 
Figure 2. Time course of modafinil in saliva in COMT Val/Val (n = 10, black circles) and Met/Met (n 
= 12, grey circles) allele carriers. Data represent means ± SEM. One data point is missing in the 
Val/Val genotype at 07:30 h on day 2 of prolonged waking (n = 9). Dashed vertical lines indicate 
100 mg modafinil administration. The maximum concentration after the second capsule occurred 
earlier and was higher in Val/Val than in Met/Met allele carriers (‘time’ x ‘genotype’: F9,104 = 6.74, p < 
0.0001).  
** p < 0.01 (unpaired, two-tailed t-test) 
 
Figure 3. Modafinil consistently improves subjective state after sleep deprivation in the Val/Val 
genotype only. The profile of mood states (POMS) was administered at 16:45 h, and van Zerssen’s 
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“Bf-S” scale at 10:45 h on day 1 (baseline) and day 2 (sleep deprivation). Data represent 
means + SEM in 10 men with the Val/Val genotype (open and filled black bars) and in 12 men with 
the Met/Met genotype (open and filled grey bars). (A) Modafinil attenuated the typical drop in vigor 
associated with prolonged wakefulness (‘condition’: F2,27.8 = 23.08, p < 0.0001). This effect was 
restricted to the Val/Val genotype and lacked completely in the Met/Met genotype (‘genotype’ x 
‘condition’: F2,27.8 = 3.33, p = 0.05). In the rested (baseline) and sleep deprived condition, vigor was 
higher in the Val/Val than in the Met/Met genotype  (‘genotype’: F1,19.9 = 7.32, p < 0.02). (B) 
Modafinil reduced depressive symptoms after sleep deprivation in Val/Val allele carriers, but not in 
Met/Met allele carriers  (‘genotype’ x ‘condition’: F2,32.8 = 4.11, p < 0.03). (C) Modafinil improved 
subjective well-being after sleep deprivation in both genotypes, yet the effect was stronger in Val/Val 
than in Met/Met allele carriers (‘genotype’ x ‘condition’: F2,39.6 = 3.38, p < 0.05). The data in panel C 
are plotted on an inverse scale. 
** p < 0.01 (unpaired and paired, two-tailed t-tests)  
* p < 0.05 (unpaired and paired, two-tailed t-tests) 
 
Figure 4. Modafinil maintains cognitive performance during sleep deprivation in the Val/Val 
genotype only. Cognitive testing including a 10-min random number generation (RNG) task preceded 
by a 10-min psychomotor vigilance task (PVT) was administered every 3 hours across 40 hours 
waking beginning 30 min after awakening. Ticks on x-axes are rounded up to the nearest hour. The 
time courses of RNG redundancy (zero-order response stereotypy), PVT lapses (reaction times [RT] > 
500 ms, transformed by √x+√1+x), slowest 10th percentile of reaction times (expressed as speed, 
1/RT), and the 90th–10th inter-percentile range of speed are illustrated. All RT < 100 ms (“errors of 
commission”) were excluded from analyses. Dashed vertical lines indicate 100 mg modafinil or 
placebo administration. Black symbols: Val/Val genotype (open circles: placebo condition, closed 
circles: modafinil condition). Grey symbols: Met/Met genotype (open circles: placebo condition, 
closed circles: modafinil condition). Top panels: Modafinil reduced redundancy after sleep 
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deprivation (‘session’: F13,309 = 2.16, p < 0.02; ‘treatment’: F1,96.8 = 16.93, p < 0.0001), yet the effect 
was higher in the Val/Val than in the Met/Met genotype (‘genotype’ x ‘treatment’: F1,96.8 = 9.94, p < 
0.003). Lower panels: Modafinil maintained during sleep deprivation all measures of sustained 
vigilant attention (PVT lapses, slowest reaction times, inter-percentile range) on baseline levels in the 
Val/Val genotype, but was virtually ineffective in the Met/Met genotype (lapses: ‘session’ x 
‘treatment’ x ‘genotype’: F26,313 = 1.71, p < 0.02; slowest reaction times: ‘session’ x ‘treatment’ x 
‘genotype’: F26,321 = 2.07, p < 0.002; inter-percentile range: ‘session’ x ‘treatment’ x ‘genotype’: 
F26,317 = 1.69, p < 0.03). Asterisks denote significant differences from respective placebo values 
(p ≤ 0.05, paired, two-tailed t-tests). 
 
Figure 5. Irrespective of Val158Met genotype of COMT and modafinil administration, prolonged 
wakefulness reduces sleep latency, and increases slow wave sleep and EEG low-frequency delta 
activity in subsequent nonREM sleep. Data represent means + SEM in 10 men with the Val/Val 
genotype (open and filled black bars) and in 12 men with the Met/Met genotype (open and filled grey 
bars). (A) Sleep deprivation shortens the time between lights-off and the first occurrence of stage 2 
sleep. (B)  Sleep deprivation prolongs the duration of slow wave sleep (nonREM sleep stages 3 & 4). 
(C) Sleep deprivation increases all-night EEG spectral power within 0.75-2.0 Hz in nonREM sleep 
(stages 1-4). 
*** p < 0.0001 (factor ‘condition’ of two-way ANOVA with between-factor ‘genotype’ [Val/Val, 
Met/Met] and within-factor ‘condition’ [mean baseline, SD-placebo, SD-modafinil]). 
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Table 1. Demographics of study participants. 
 Val/Val Met/Met p 
Caucasian/Asian ethnicity 8/2 12/0  
Age (years) 23.9 ± 0.8 23.0 ± 0.6 0.35 
Body-mass-index (kg/m2) 21.9 ± 0.6 22.3 ± 0.4 0.61 
Alcohol consumption (drinks/w) 2.2 ± 0.6 3.0 ± 1.0 0.50 
Caffeine consumption (mg/d) 137.0 ± 67.6 146.7 ± 36.0 0.90 
Trait Anxiety Inventory (44) 38.6 ± 3.4 36.3 ± 2.2 0.57 
Epworth Sleepiness Scale (45) 6.9 ± 0.7 7.2 ± 0.6 0.78 
Chronotype    
MEQ 49.3 ± 3.0 47.5 ± 2.8 0.67 
MCTQ 5.1 ± 0.4 4.9 ± 0.3 0.69 
Values represent means ± SEM (Val/Val genotype, n = 10; Met/Met genotype, n = 12). p-values: 
unpaired, two-tailed t-tests. 
The estimates of caffeine consumption were based on the following average caffeine content per 
serving: Coffee, 100 mg; Ceylon or green tea, 30 mg; Cola drink (2 dl), 40 mg; Energy drink (2 dl), 
80 mg; Chocolate (100 g), 50 mg. MEQ: Horne-Östberg Morningness-Eveningness Questionnaire  
(46). MCTQ: Munich ChronoType Questionnaire (47). The reported MCTQ values indicate the mid-
sleep time on leisure days including an estimated correction for the sleep-debt accumulated during the 
workweek (MSFsc). 
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Table 2. Modafinil attenuates the sleep deprivation-induced impairment in accuracy and speed on a 2-
back task. 
 Placebo Modafinil 
 Baseline Sleep deprivation Baseline Sleep deprivation 
Val/Val genotype     
 Reaction Time (ms) 690.6 ± 42.2 840.1 ± 65.3 * 708.9 ± 44.6 772.3.0 ± 46.9 
 Incorrect (%) 6.3 ± 3.0 11.8 ± 4.0 * 7.2 ± 2.8 8.5 ± 2.6 
Met/Met genotype     
 Reaction Time (ms) 746.7 ± 45.1 808.5 ± 46.2 742.2 ± 50.1 747.9 ± 51.4 
 Incorrect (%) 4.3 ± 1.3 9.5 ± 2.9 * 5.1 ± 2.0 7.5 ± 2.3 
 Values represent means ± SEM in 10 subject with Val/Val genotype and 12 subjects with Met/Met 
genotype. The 2-back task was performed at 6.75 (baseline) and 30.75 hours (sleep deprivation) into 
prolonged waking. Accuracy: Percentage of incorrect responses. Irrespective of genotype, sleep 
deprivation prolonged reaction time (‘condition’: F2,25.4 = 4.7, p < 0.02) and increased of incorrect 
responses (‘condition’: F2,29.6 = 4.7, p < 0.02). Modafinil attenuated the impairments induced by sleep 
deprivation. 
* p < 0.04 (two-tailed, paired t-tests) 
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